Match!

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study

Published on Sep 1, 2011in Lancet Oncology35.386
· DOI :10.1016/S1470-2045(11)70214-5
K Gelmon74
Estimated H-index: 74
(BC Cancer Agency),
Marc Tischkowitz10
Estimated H-index: 10
(JGH: Jewish General Hospital)
+ 11 AuthorsAmit M. Oza54
Estimated H-index: 54
Sources
Abstract
Summary Background Olaparib (AZD2281) is a small-molecule, potent oral poly(ADP-ribose) polymerase (PARP) inhibitor. We aimed to assess the safety and tolerability of this drug in patients without BRCA1 or BRCA2 mutations with advanced triple-negative breast cancer or high-grade serous and/or undifferentiated ovarian cancer. Methods In this phase 2, multicentre, open-label, non-randomised study, women with advanced high-grade serous and/or undifferentiated ovarian carcinoma or triple-negative breast cancer were enrolled and received olaparib 400 mg twice a day. Patients were stratified according to whether they had a BRCA1 or BRCA2 mutation or not. The primary endpoint was objective response rate by Response Evaluation Criteria In Solid Tumors (RECIST). All patients who received treatment were included in the analysis of toxic effects, and patients who had measurable lesions at baseline were included in the primary efficacy analysis. This trial is registered at ClinicalTrials.gov, number NCT00679783. Findings 91 patients were enrolled (65 with ovarian cancer and 26 breast cancer) and 90 were treated between July 8, 2008, and Sept 24, 2009. In the ovarian cancer cohorts, 64 patients received treatment. 63 patients had target lesions and therefore were evaluable for objective response as per RECIST. In these patients, confirmed objective responses were seen in seven (41%; 95% CI 22–64) of 17 patients with BRCA1 or BRCA2 mutations and 11 (24%; 14–38) of 46 without mutations. No confirmed objective responses were reported in patients with breast cancer. The most common adverse events were fatigue (45 [70%] of patients with ovarian cancer, 13 [50%] of patients with breast cancer), nausea (42 [66%] and 16 [62%]), vomiting (25 [39%] and nine [35%]), and decreased appetite (23 [36%] and seven [27%]). Interpretation Our study suggests that olaparib is a promising treatment for women with ovarian cancer and further assessment of the drug in clinical trials is needed. Funding AstraZeneca.
  • References (31)
  • Citations (677)
📖 Papers frequently viewed together
1,110 Citations
200543.07Nature
14 Authors (Hannah Farmer, ..., Alan Ashworth)
3,482 Citations
538 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
References31
Newest
1007 Background: A randomized phase II study in mTNBC suggested that iniparib (I), an anticancer agent with PARP inhibitory activity, added to GC improved overall survival (OS), without potentiating GC toxicity (O’Shaughnessy et al. NEJM 2011). This confirmatory study evaluated the safety and efficacy of GC with or without I in a similar mTNBC pt population. Methods: This randomized, open-label phase III study enrolled pts ≥18 years with mTNBC, measurable disease, and ≤2 prior cytotoxic regimens...
214 CitationsSource
#1Sumanta K. Pal (City of Hope National Medical Center)H-Index: 45
#2Barrett H. ChildsH-Index: 22
Last. Mark D. Pegram (UM: University of Miami)H-Index: 52
view all 3 authors...
Triple negative breast cancer (TNBC) is an aggressive clinical phenotype characterized by lack of expression (or minimal expression) of estrogen receptor (ER) and progesterone receptor (PR) as well as an absence of human epidermal growth factor receptor-2 (HER2) overexpression. It shows substantial overlap with basal-type and BRCA1-related breast cancers, both of which also have aggressive clinical courses. However, this overlap is not complete, and the expression of ER, PR, and HER2 has been no...
169 CitationsSource
#1Cynthia Osborne (Texas Oncology)H-Index: 11
#2John Pippen (Texas Oncology)H-Index: 22
Last. Charles BradleyH-Index: 7
view all 8 authors...
Background Triple-negative breast cancers have inherent defects in DNA repair, making this cancer a rational target for therapy based on poly(adenosine diphosphate–ribose) polymerase (PARP) inhibition. Methods We conducted an open-label, phase 2 study to compare the efficacy and safety of gemcitabine and carboplatin with or without iniparib, a small molecule with PARP-inhibitory activity, in patients with metastatic triple-negative breast cancer. A total of 123 patients were randomly assigned to...
617 CitationsSource
#1Stan B. KayeH-Index: 96
#2Bella KaufmanH-Index: 45
Last. James Carmichael (AstraZeneca)H-Index: 27
view all 9 authors...
22 Citations
#1Bryan T. HennessyH-Index: 53
#2Kirsten TimmsH-Index: 26
Last. Gordon B. MillsH-Index: 157
view all 19 authors...
Purpose The prevalence of BRCA½ mutations in germline DNA from unselected ovarian cancer patients is 11% to 15.3%. It is important to determine the frequency of somatic BRCA½ changes, given the sensitivity of BRCA-mutated cancers to poly (ADP ribose) polymerase-1 (PARP1) inhibitors and platinum analogs. Patients and Methods In 235 unselected ovarian cancers, BRCA½ was sequenced in 235, assessed by copy number analysis in 95, and tiling arrays in 65. 113 tumors were sequenced for TP53. BRCA½ tran...
217 CitationsSource
#1Andrew Tutt ('KCL': King's College London)H-Index: 56
#2Mark E. Robson (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 67
Last. James Carmichael (AstraZeneca)H-Index: 27
view all 15 authors...
Summary Background Olaparib, a novel, orally active poly(ADP-ribose) polymerase (PARP) inhibitor, induced synthetic lethality in BRCA -deficient cells. A maximum tolerated dose and initial signal of efficacy in BRCA -deficient ovarian cancers have been reported. We therefore assessed the efficacy, safety, and tolerability of olaparib alone in women with BRCA1 or BRCA2 mutations and advanced breast cancer. Methods Women (aged ≥18 years) with confirmed BRCA1 or BRCA2 mutations and recurrent, advan...
1,577 CitationsSource
#1Peter C.C. FongH-Index: 23
#2Timothy A. YapH-Index: 31
Last. Stan B. Kaye (National Health Service)H-Index: 96
view all 18 authors...
Purpose Selective tumor cell cytotoxicity can be achieved through a synthetic lethal strategy using poly(ADP)-ribose polymerase (PARP) inhibitor therapy in BRCA1/2 mutation carriers in whom tumor cells have defective homologous recombination (HR) DNA repair. Platinum-based chemotherapy responses correlate with HR DNA repair capacity. Olaparib is a potent, oral PARP inhibitor that is well tolerated, with antitumor activity in BRCA1/2 mutation carriers. Patients and Methods Patients with BRCA1/2-m...
642 CitationsSource
#1Rebecca DentH-Index: 29
Last. James CarmichaelH-Index: 27
view all 10 authors...
1018 Background: Triple negative breast cancer (TNBC) shares molecular characteristics with BRCA1-/- breast cancer (BC). Preclinical and clinical data show that BRCA1-/- BC and TNBC are sensitive to inhibition of PARP1, an enzyme necessary for DNA repair and other critical cell functions. This phase 1 study evaluated the tolerability of olaparib, a potent PARP1 inhibitor, combined with weekly paclitaxel in patients with metastatic TNBC. This trial served as a safety evaluation to be followed by ...
56 CitationsSource
#1Michèle Rouleau (Laval University)H-Index: 21
#2Anand Patel (Mayo Clinic)H-Index: 4
Last. Guy G. Poirier (Laval University)H-Index: 69
view all 5 authors...
Recent findings have thrust poly(ADP-ribose) polymerases (PARPs) into the limelight as potential chemotherapeutic targets. To provide a framework for understanding these recent observations, we review what is known about the structures and functions of the family of PARP enzymes, and then outline a series of questions that should be addressed to guide the rational development of PARP inhibitors as anticancer agents.
784 CitationsSource
#1Peter C.C. FongH-Index: 23
#2D. S. Boss (NKI-AVL: Netherlands Cancer Institute)H-Index: 13
Last. Johann S. de BonoH-Index: 101
view all 15 authors...
Background The inhibition of poly(adenosine diphosphate [ADP]–ribose) polymerase (PARP) is a potential synthetic lethal therapeutic strategy for the treatment of cancers with specific DNA-repair defects, including those arising in carriers of a BRCA1 or BRCA2 mutation. We conducted a clinical evaluation in humans of olaparib (AZD2281), a novel, potent, orally active PARP inhibitor. Methods This was a phase 1 trial that included the analysis of pharmacokinetic and pharmacodynamic characteristics ...
2,378 CitationsSource
Cited By677
Newest
#1Elizabeth K. Lee (Harvard University)H-Index: 3
#2Ursula A. Matulonis (Harvard University)H-Index: 60
INTRODUCTION Poly (ADP-ribose) polymerase (PARP) inhibitors have demonstrated significant anticancer activity in cancers harboring homologous recombination deficiency (HRD), exemplified by high grade serous ovarian cancer (HGSC). PARP inhibitors (PARPi) are being used in women with newly diagnosed ovarian cancer as well as in the recurrent setting. PARPi combination therapies are in development. AREAS COVERED This review discusses the treatment of ovarian cancer, key PARPi clinical trials, mecha...
Source
#1Xuanzhang Huang (PRC: China Medical University (PRC))H-Index: 15
#2Han Jia (PRC: China Medical University (PRC))
Last. Xin Zhou (PRC: China Medical University (PRC))
view all 7 authors...
Background: The prognostic factors for efficacy of poly(ADP-ribose) polymerase (PARP) inhibitors in ovarian cancer remain unknown. The purpose of this study is to evaluate the efficacy of PARP inhibitors and to explore their prognostic factors in ovarian cancer. Methods: PubMed, Embase, and conference databases were searched for relevant prospective clinical trials. The primary outcomes included overall survival (OS), progression-free survival (PFS), and their prognostic factors. Secondary outco...
Source
#1Yu Zhang (HUST: Huazhong University of Science and Technology)H-Index: 15
#2Huiping Hu (HUST: Huazhong University of Science and Technology)H-Index: 1
Last. Kaiping Wang (HUST: Huazhong University of Science and Technology)H-Index: 16
view all 11 authors...
Abstract Multifunctional magnetic nanoparticles (MNPs) were widely used for ablation of cancer cells because of their potential on physical treatment. Herein, we developed the “cell targeting destructive” multifunctional polymeric nanoparticles (named as HA-Olb-PPMNPs) based on PEI-PLGA co-loaded with the anticancer drug Olaparib (Olb) and superparamagnetic iron oxide nanoparticles (Fe3O4 NPs), and further coated with a low molecular weight hyaluronic acid (HA) on its surface. Due to the high af...
Source
#1Li Yin (Third Military Medical University)H-Index: 1
#2Jiang-Jie Duan (Third Military Medical University)H-Index: 8
Last. Shi-Cang Yu (Third Military Medical University)H-Index: 20
view all 4 authors...
Triple-negative breast cancer (TNBC), a specific subtype of breast cancer that does not express estrogen receptor (ER), progesterone receptor (PR), or human epidermal growth factor receptor 2 (HER-2), has clinical features that include high invasiveness, high metastatic potential, proneness to relapse, and poor prognosis. Because TNBC tumors lack ER, PR, and HER2 expression, they are not sensitive to endocrine therapy or HER2 treatment, and standardized TNBC treatment regimens are still lacking....
Source
#1Tomoko Watanabe (Tokyo Medical and Dental University)
#2Takayuki Honda (Tokyo Medical and Dental University)H-Index: 3
Last. Kenji TamuraH-Index: 29
view all 13 authors...
Homologous recombination deficiency (HRD), which influences the efficacy of PARP inhibitor- and platinum agent-based therapies, is a prevalent phenotype of breast cancer in adolescents and young adults (AYAs; 15–39 years old). However, HRD score, indicating HRD status, is not routinely assessed in the breast oncology clinic, particularly in patients without germline BRCA1/2 mutations. Hence, we sought to develop a model for determining HRD status based on genetic and clinicopathological factors....
Source
#1Neha Chopra (ICR: Institute of Cancer Research)H-Index: 3
#2Holly Tovey (ICR: Institute of Cancer Research)H-Index: 5
Last. Frances Daley (ICR: Institute of Cancer Research)H-Index: 14
view all 22 authors...
Triple negative breast cancer (TNBC) encompasses molecularly different subgroups, with a subgroup harboring evidence of defective homologous recombination (HR) DNA repair. Here, within a phase 2 window clinical trial, RIO trial (EudraCT 2014-003319-12), we investigate the activity of PARP inhibitors in 43 patients with untreated TNBC. The primary end point, decreased Ki67, occured in 12% of TNBC. In secondary end point analyses, HR deficiency was identified in 69% of TNBC with the mutational-sig...
Source
#1Zheng Zhong (NUS: National University of Singapore)H-Index: 2
#2Jia Yu (NUS: National University of Singapore)H-Index: 6
Last. Babita Madan (NUS: National University of Singapore)H-Index: 22
view all 4 authors...
Since the discovery of the first mammalian Wnt proto-oncogene in virus-induced mouse mammary tumors almost four decades ago, Wnt signaling pathway and its involvement in cancers have been extensively investigated. Activation of this evolutionarily conserved pathway promotes cancer development via diverse mechanisms. Cancer is a complex disease and one outstanding conceptual framework for understanding its biology is the "Hallmarks of Cancer". In this review, we focus on the involvement of Wnt si...
Source
#1Naveen Singh (IUPUI: Indiana University – Purdue University Indianapolis)H-Index: 1
#2S. Louise Pay (IUPUI: Indiana University – Purdue University Indianapolis)H-Index: 2
Last. Edward A. Motea (IUPUI: Indiana University – Purdue University Indianapolis)H-Index: 1
view all 5 authors...
Poly-(ADP-ribose) polymerase 1 (PARP1) is commonly known for its vital role in DNA damage response and repair. However, its enzymatic activity has been linked to a plethora of physiological and pathophysiological transactions ranging from cellular proliferation, survival and death. For instance, malignancies with BRCA1/2 mutations heavily rely on PARP activity for survival. Thus, the use of PARP inhibitors is a well-established intervention in these types of tumors. However, recent studies indic...
1 CitationsSource
#1Tzu-Ting HuangH-Index: 1
#2Erika J. LampertH-Index: 1
Last. Jung-Min LeeH-Index: 18
view all 4 authors...
Abstract Ovarian cancer is the most lethal gynecological malignancy worldwide although exponential progress has been made in its treatment over the last decade. New agents and novel combination treatments are on the horizon. Among many new drugs, a series of PI3K/AKT/mTOR pathway (referred to as the PI3K pathway) inhibitors are under development or already in clinical testing. The PI3K pathway is frequently upregulated in ovarian cancer and activated PI3K signaling contributes to increased cell ...
2 CitationsSource
Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) have transformed the treatment landscape in front-line and recurrent high-grade serous ovarian cancer. Maintenance strategies with PARPi have been assessed in randomized phase III trials in ovarian cancer; switch maintenance in the case of olaparib, niraparib, and rucaparib; and concurrent followed by continuation maintenance with veliparib. These studies have shown progression-free survival advantage with PARPi maintenance, with no major ad...
1 CitationsSource